Could a lower drug dose be safer and just as effective for kids with rare tumor?

NCT ID NCT07656909

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two doses of sirolimus (low vs high) given with prednisolone to children aged 0-18 who have a rare blood vessel tumor called kaposiform hemangioendothelioma with a serious blood clotting problem (Kasabach-Merritt phenomenon). The goal is to see if the lower dose works just as well to restore platelet counts but causes fewer side effects. About 76 children will take part and be monitored with blood tests and imaging.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KAPOSIFORM HEMANGIOENDOTHELIOMA (KHE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

kaposiform hemangioendothelioma Kasabach-Merritt syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • West China Hospital of Sichuan University

    RECRUITING

    Chengdu, Sichuan, 610041, China

    Contact Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••